My First Week Here at the U of M Lupus Research Facilities
My name is Brianna Lauer and I first joined the Lupus Foundation of Minnesota through their Summer Fellowship Program, which is a program that gives undergraduate students the chance to work alongside faculty at the University of Minnesota and work on funded programs dealing with lupus. I became interested in lupus research through the amazing guidance of Dr. Emily Gillespie and her dedication to this research.
I wanted to talk about my experiences this summer working in the laboratory here at ...Continue Reading →
New Faces to Lupus Research: Student Summer Research Fellows
If you attended the Lupus Food and Wine Classic in June, you might remember the group of enthusiastic young adults who greeted you as you entered Nickelodeon Universe and escorted you to the registration table. Those students are this year’s Lupus Foundation of Minnesota (LFM)Summer Research Fellows, and we are fortunate to be hosting them in our laboratories at the University of Minnesota while they participate in a lupus research project and learn what full-time research is really like. (Spoiler ...Continue Reading →
Lupus patients invited to Biovid Corp. survey
Biovid Corp. would like to invite patients to participate in a 20-minute online survey discussing experiences and attitudes toward the management of your lupus condition. The survey is strictly for market research purposes; there will be absolutely no sales or promotional activities in conjunction with this survey. Your responses are completely confidential. Qualified participants will receive a check at the end of the study for $50. If you are interested in participating in this survey, please email Dusten Brennan at Biovid ...Continue Reading →
Increased severity of lupus and African-American women focus of Lupus Foundation of Minnesota-funded research at University of Minnesota
Researchers who seek new biomarkers for human diseases may have many goals. In the field of lupus research, we would like to find biomarkers that could make the disease easier to diagnose, improve the management of disease activity, predict when a flare is likely to occur, and help physicians decide which medications to use (or avoid) in a particular patient.Continue Reading →
Thanks to advances in genomic and proteomic technologies over the past 10 years, lupus researchers have been successful in ...
A new drug is approved, new questions arise. So how do we find the answers?
Fortunately, many researchers have ideas about where to look for answers, because we know that Benlysta works by reining in a type of immune cells called B cells. B cells play an important role in the normal immune response, but when inappropriately activated in a lupus patient, they produce harmful elements that cause the damaging effects seen in SLE. Researchers think that measuring these may provide clues to help us determine whether an individual patient is likely to respond to ...Continue Reading →
A new drug is approved. What’s next?
We finally get to ask that question about lupus, after the FDA approved Benlysta, the first new drug approved for SLE in over 50 years, in March 2011.
Patients and researchers alike are asking questions … Who needs to take this drug? How is it different from the medicines that doctors were already using? How do we know it’s going to work? How do we know that it’s going to work better than those other medications?
Continue Reading →
Lifetime Risk of Adult-Onset Autoimmune Diseases
There is a recent (within the past year) article from Mayo Clinic that I’ve attached here, that I think addresses some questions about the incidence of lupus in Minnesota. It is focused on the overall lifetime risk for development of autoimmune diseases, including SLE.
“The Lifetime Risk of Adult-Onset Rheumatoid Arthritis and Other Inflammatory Autoimmune Rheumatic Diseases”
Article published in:
Continue Reading →
Arthritis & Rheumatism
Vol. 63, No. 3